Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 9

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 9
---
 investors in this offering,
and investors purchasing shares or other securities in the future could have rights superior to existing stockholders, including investors
who purchase shares of common stock in this offering. The price per share at which we sell additional shares of our common stock or securities
convertible into common stock in future transactions, may be higher or lower than the price per share in this offering. As a result, purchasers
of the shares we sell, as well as our existing stockholders, will experience significant dilution if we sell at prices significantly below
the price at which they invested.

We will have broad discretion in the use of the net proceeds from this offering and, despite our efforts, we may use the net proceeds in a manner that does not increase the value of your investment.

We intend to use the net proceeds
from this offering for general corporate purposes and working capital. Our management will have broad discretion over the use and investment
of the net proceeds from this offering, and, accordingly, investors in this offering will need to rely upon the judgment of our management
with respect to the use of proceeds, with only limited information concerning our specific intentions. We may use the net proceeds in
ways that do not improve our operating results or increase the value of your investment.

<div align='center'>S-4</div>

Intellectual Property Risk Factors

By working with research collaborators patent rights may be jointly owned by different parties.

Certain
of our licensors may have relied on third-party consultants or collaborators such that our licensors are not the sole and exclusive owners
of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us for
such jointly owned patents may not be valid. Absent an agreement, each joint owner can independently sell, license, or otherwise exploit
the jointly owned patent without the approval of the other joint owner(s) and without having to account to each other for their revenues.
Without the cooperation of all joint owners, none can grant an exclusive license to a third party. Further, a jointly owned patent cannot
be enforced unless all of the owners join in the lawsuit. If a co-owner refuses to participate, the lawsuit cannot proceed. Certain of
our in-licensed patents from Xencor show joint ownership between Xencor and a third party. Xencor provided representations and warrants
as to its ability to grant the rights provided in the license. In addition, Xencor is required to indemnify us as to any breach of its